Editing Digoxin (section)

===Pharmacomicrobiomics===
The bacteria ''[[Eggerthella lenta]]'' has been linked to a decrease in the toxicity of digoxin.<ref>{{Cite web|title=PharmacoMicrobiomics|url=http://pharmacomicrobiomics.com/select/?q=2|access-date=2020-08-13|website=pharmacomicrobiomics.com|archive-date=2021-06-02|archive-url=https://web.archive.org/web/20210602212845/https://c.statcounter.com/6166637/0/607d5329/0/|url-status=live}}</ref> These effects have been studied through comparisons of North Americans and Southern Indians, in which a reduced digoxin metabolite profile correlates with ''E. lenta'' abundance.<ref>{{cite journal | vauthors = Mathan VI, Wiederman J, Dobkin JF, Lindenbaum J | title = Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora | journal = Gut | volume = 30 | issue = 7 | pages = 971–7 | date = July 1989 | pmid = 2759492 | pmc = 1434295 | doi = 10.1136/gut.30.7.971 }}</ref> Further studies have also revealed an increase in digoxin toxicity when used alongside erythromycin or tetracycline, the researches attributed this to the decrease in the ''E. lenta'' population.<ref>{{cite journal | vauthors = Lindenbaum J, Rund DG, Butler VP, Tse-Eng D, Saha JR | title = Inactivation of digoxin by the gut flora: reversal by antibiotic therapy | journal = The New England Journal of Medicine | volume = 305 | issue = 14 | pages = 789–94 | date = October 1981 | pmid = 7266632 | doi = 10.1056/NEJM198110013051403 }}</ref>